Liver Transplantation for Metastatic Neuroendocrine Tumors

Authors:
  • KOKarl Jürgen Oldhafer
    Karl Jürgen Oldhafer
  • AWArved Weimann
    Arved Weimann
  • HSHans Jürgen Schlitt
    Hans Jürgen Schlitt
  • GSGeorg Friedrich Wilhelm Scheumann
    Georg Friedrich Wilhelm Scheumann
  • PFPeer Flemming
    Peer Flemming
  • BRBurkhardt Ringe
    Burkhardt Ringe
  • RPRudolf Pichlmayr
    Rudolf Pichlmayr
Publisher website
Google Scholar
Abstract
This article describes the experience with liver transplantation in patients with irresectable neuroendocrine hepatic metastases. Liver transplantation has become an established therapy in primary liver cancer. On contrast, there is little experience with liver transplantation in secondary hepatic tumors. So far, in the majority of patients being transplanted for irresectable liver metastases, long-term results have been disappointing because of early tumor recurrence. Because of their biologically less aggressive nature, the metastases of neuroendocrine tumors could represent a justified indication for liver grafting. In a retrospective study, the data of 12 patients who underwent liver transplantation for irresectable neuroendocrine hepatic metastases were analyzed regarding survival, tumor recurrence, and symptomatic relief. Nine of 12 patients currently are alive with a median survival of 55 months (range, 11.0 days to 103.5 months). The operative mortality was 1 of 12, 2 patients died because of septic complications or tumor recurrences or both 6.5 months and 68.0 months after transplantation. All patients had good symptomatic relief after hepatectomy and transplantation. Four of the nine patients who are alive have no evidence of tumor with a follow-up of 2.0, 57.0, 58.0, and 103.5 months after transplantation. In selected patients, liver transplantation for irresectable neuroendocrine hepatic metastases may provide not only long-term palliation but even cure. Regarding the shortage of donor organs, liver grafting for neuroendocrine metastases should be considered solely in patients without evidence of extrahepatic tumor manifestation and in whom all other treatment methods are no longer effective.

This publication has 34 references indexed in Scilit: